Funded in part by Danone
Effect of increased water intake on plasma copeptin in patients with chronic kidney disease: results from a pilot randomised controlled trial
Sontrop JM, Huang SH, Garg AX, Moist L, House AA, Gallo K, Clark WF
BMJ open · 29 citations
Review labels
Neutral facts our review recorded about how this study was done. They describe method, never whether we like the result.
How it was studied
- Design
- Randomized controlled trial (indexed by PubMed)
- Studied in
- People
- Main outcome
- Health markers and function
Who paid for it
- Funding
- Industry funded
- Company
- Danone
Based on 1 listed funder(s).
Publication
- Published
- 2015-11-01 · BMJ Open · vol. 5 · issue 11 · p. e008634
- Publisher
- BMJ
- Cited
- 39 citations · more than 96% of similar papers · 5.1× the field average
- Impact
- Top 10% most cited in its field
- References
- 56 works
- Access
- Open access (journal) · CC-BY-NC
- Research areas
- Electrolyte and hormonal disorders · Ion Transport and Channel Regulation · Sodium Intake and Health
- Keywords
- Copeptin, Medicine, Kidney disease, Vasopressin, Internal medicine, Renal function, Urine, Urinalysis, Randomized controlled trial, Endocrinology, Urine osmolality, Gastroenterology
- MeSH
- kidney, humans, glycopeptides, glomerular filtration rate, drinking, aged, middle aged, canada, female, male, renal insufficiency, chronic, biomarkers
7 authors
From CA
- Jessica M. SontropWestern University; London Health Sciences Centre
- Shi-Han HuangLondon Health Sciences Centre
- Amit X. GargWestern University; London Health Sciences Centre
- Louise M. MOISTWestern University; London Health Sciences Centre
- Andrew A. HouseLondon Health Sciences Centre
- Kerri GalloLondon Health Sciences Centre
Abstract
Objectives
Increased water intake may have a beneficial effect on the kidney through suppression of plasma vasopressin. We examined the effect of increased water intake on plasma copeptin (a marker of vasopressin) over 6 weeks in patients with chronic kidney disease.
Design
Secondary analysis of a randomised controlled parallel-group pilot trial.
Setting
Canada, 2012-2013.
Participants
28 patients with stage 3 chronic kidney disease randomised (2:1) to a hydration (n=17) or control group (n=11).
Intervention
The hydration group was coached to increase water intake by up to 1.5 L/day for 6 weeks. The control group was asked to maintain regular water intake.
Measures and outcomes
Participants provided blood and 24 h urine samples at baseline and 6 weeks. Change in plasma copeptin was compared within and between study groups.
Results
Participants were 64% male with a mean age of 62 years and an estimated glomerular filtration rate of 40 mL/min/1.73 m(2). Between baseline and 6 weeks, 24 h urine volume increased by 0.7 L/day in the hydration group, rising from 2.3 to 3.0 L/day (p=0.01), while decreasing by 0.3 L/day among controls, from 2.0 to 1.7 L/day (p=0.07); between-group difference: 0.9 L/day (95% CI 0.37 to 1.46; p=0.002). In the hydration group, median copeptin decreased by 3.6 pmol/L, from 15.0 to 10.8 pmol/L (p=0.005), while remaining stable among controls at 19 pmol/L (p=0.76; p=0.19 for the between-group difference in median change); the between-group difference in mean change was 5.4 pmol/L (95% CI -1.2 to 12.0; p=0.11).
Conclusions
Adults with stage 3 chronic kidney disease can be successfully randomised to drink approximately 1 L more per day than controls. This increased water intake caused a significant decrease in plasma copeptin concentration. Our larger 12-month trial will examine whether increased water intake can slow renal decline in patients with chronic kidney disease.
Trial registration number
NCT01753466.
Abstract via Europe PMC. Copyright remains with the authors or publisher (CC BY-NC).
Community trust
Loading…
How much do you trust this study's findings?
Comments
Sign in to rate, comment on or flag this study.Sign inSomething wrong here?
Flag this study if its information, labels or funding look wrong. An editor reviews every flag.
Sign in to rate, comment on or flag this study.Sign inEducational information about published research. Not medical advice, and not a recommendation to start or stop anything.